Xtant Medical Holdings, Inc. (XTNT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 13, 2026, by Xtant Medical Holdings, Inc., a Delaware corporation headquartered in Belgrade, Montana. The filing primarily serves to announce the Company's financial results for the three months ended March 31, 2026 (First Quarter 2026) and to disclose the date of the upcoming 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
The Company utilizes non-GAAP adjusted EBITDA as a key performance metric. The filing defines this measure as net income (loss) adjusted for:
- Depreciation and amortization expense.
- Interest expense, net, and tax benefit (expense).
- Non-cash compensation.
- Divestiture/acquisition-related income and expenses.
- Acquisition-related fair value adjustments.
- Unrealized foreign currency translation gain or loss.
- Separation-related expenses.
Management states this metric is used to assess core operational performance, facilitate period-over-period comparisons, and guide resource allocation decisions.
Material Changes and Comparisons
The filing text does not contain specific data regarding material changes in financial performance versus the prior comparable period. It only confirms that the Company has announced its Q1 2026 results and that the press release includes reconciliations of non-GAAP measures to GAAP net income.
Guidance, Outlook, and Corporate Events
Annual Meeting Announcement: The Company announced that its 2026 Annual Meeting of Stockholders will be held on August 7, 2026. The exact time and location will be specified in the proxy statement, anticipated to be printed on or about June 11, 2026.
Stockholder Proposals: Due to the change in the meeting date by more than 30 days from the prior year, stockholders wishing to submit proposals under Rule 14a-8 must do so by May 23, 2026. Similarly, director nominations and other proposals under the Company's Bylaws must be received by the same date.
Universal Proxy Rules: Stockholders intending to solicit proxies for director nominees other than the Company's nominees must provide written notice by June 9, 2026.
Guidance and Risks: The provided text does not contain specific forward-looking guidance, risk factors, or commentary on contingencies beyond the standard definitions of non-GAAP measures and the procedural details of the Annual Meeting.
Investor Verification Checklist
- Review Exhibit 99.1: Access the full press release to obtain specific Q1 2026 revenue, net income, and cash flow figures, which are absent from this 8-K summary.
- Analyze Non-GAAP Reconciliations: Verify the magnitude of adjustments (e.g., non-cash compensation, acquisition costs) made to reach adjusted EBITDA to understand the divergence from GAAP results.
- Confirm Annual Meeting Logistics: Monitor the upcoming proxy statement (expected mid-June 2026) for the specific time and location of the August 7, 2026, meeting.
- Check Proposal Deadlines: Note the May 23, 2026, deadline for stockholder proposals and director nominations if intending to participate in the governance process.